Screener
Sarepta Therapeutics, Inc. SRPT Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|
| Non-cash interest expense | 19,006 | 2,602 |
| Non‑cash inventory write‑downs for obsolescence | 11,599 | — |
| Reduction in the carrying amounts of the right of use assets | 6,322 | 7,956 |
| Loss on strategic investments | 2,160 | 54,007 |
| Accretion of investment discount, net | (1,435) | (3,778) |
| Other | (1,298) | 701 |
| Changes in operating assets and liabilities, net: | ||
| Decrease in accounts receivable | 21,409 | 74,693 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s net gains (losses) on investments?
- Sarepta Therapeutics, Inc. (SRPT) reported net gains (losses) on investments of -$448K in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s net gains (losses) on investments changed year-over-year?
- Sarepta Therapeutics, Inc.'s net gains (losses) on investments decreased by 101.2% year-over-year, from $36.72M to -$448K.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Sarepta Therapeutics, Inc.'s net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude